ENTA

Over the past six months, Enanta Pharmaceuticals' stock has been impacted by several events. In September 2026, the company announced participation in investor conferences, and H.C. Wainwright reiterated a 'Buy' rating and a $20.00 price target, citing positive Phase 3 trial results for a competing chronic spontaneous urticaria treatment as favorable for Enanta's EDP-978. In August 2026, the company reported fiscal third-quarter financial results that missed analyst expectations, with adjusted earnings per share of -$0.67 and revenue of $14.4 million, a 21% decline from the previous year due to decreased royalty revenue from AbbVie's MAVYRET/MAVIRET. Deep Track Capital and Farallon Capital group also disclosed their stakes in Enanta. In June 2026, Enanta's partner AbbVie received European Commission approval of MAVIRET® for acute Hepatitis C Virus, and the stock saw a rise on RSV drug trial plans. In May 2026, the company reported fiscal second-quarter financial results. From September 2025 to September 2026, the stock price increased by 46.65%, and by 99.57% over the last 12 months, though it decreased by 3.37% in the past month. The stock hit a 52-week high of $17.15 and a 52-week low of $7.05 within the last year.